The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL-6 mAb) and Bortezomib versus Bortezomib Alone in Patients with Relapsed or Refractory Multiple Myeloma.

Orlowski RZ, Gercheva L, Williams C, Sutherland H, Robak T, Masszi T, Goranova-Marinova V, Dimopoulos MA, Cavenagh JD, Spička I, Maiolino A, Suvorov A, Bladé J, Samoylova O, Puchalski TA, Reddy M, Bandekar R, van de Velde H, Xie H, Rossi JF.
Am J Hematol. 2014 Oct 8. doi: 10.1002/ajh.23868. [Epub ahead of print]
PMID: 25294016 [PubMed - as supplied by publisher]
Related citations
READ MORE

Posted: November 25, 2014

Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents.

Jimenez-Zepeda VH, Reece DE, Trudel S, Chen C, Tiedemann R, Kukreti V.
Bone Marrow Transplant. 2014 Oct 27. doi: 10.1038/bmt.2014.237. [Epub ahead of print]
PMID: 25347006 [PubMed - as supplied by publisher]
Related citations
READ MORE

Posted: November 25, 2014

Plerixafor is superior to conventional chemotherapy for first-line stem cell mobilisation, and is effective even in heavily pretreated patients.

Clark RE, Bell J, Clark JO, Braithwaite B, Vithanarachchi U, McGinnity N, Callaghan T, Francis S, Salim R.
Blood Cancer J. 2014 Oct 31;4:e255. doi: 10.1038/bcj.2014.79.
PMID: 25360901 [PubMed - in process] Free PMC Article
Related citations
READ MORE

Posted: November 25, 2014

Page 84 of 87« First...102030...8283848586...Last »